Citations

Clear

3030 citation(s) found for "Susan, M".

Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
Carrillo, María C. , Brashear, H. Robert, Logovinsky, Veronika, Ryan, J. Michael, Feldman, Howard , Siemers, Eric , Abushakra, Susan, Hartley, Dean M. , Petersen, Ronald C. , Khachaturian, Ara S. , Sperling, Reisa Anne , Feldman, Howard H

Mayo Clinic

Alzheimer's & Dementia | February 11, 2013 | Volume: 9 | Issue: 2 | Pages: 123

10.1016/j.jalz.2012.12.004 | PMID 23411394 Get It

Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is sufficient to initiate prevention studies and allow us to believe prevention of AD is possible. Current research and recently revised criteria for the diagnosis of AD by the National Institutes on Aging and the Alzheimer's Association suggest a continuum of disease from preclinical asymptomatic to symptomatic Alzheimer's dementia. In light of these revised criteria, the possibility of secondary prevention and even primary prevention is under discussion. The Alzheimer's Association Research Roundtable convened a meeting to discuss the rationale and feasibility of conducting secondary prevention trials in AD.
A Multicenter, Prospective Study to Evaluate the Use of Contrast Stress Echocardiography in Early Menopausal Women at Risk for Coronary Artery Disease: Trial Design and Baseline Findings
Bernier, Mathieu , Hagen, Mary E., Eifert-Rain, Susan, Bott‐Kitslaar, Dalene , Wilansky, Susan , Castelló, Ramón, Bhat, Gajanan , Pellikka, Patricia A. , Best, Patricia J.M. , Hayes, Sharonne N. , Abdelmoneim, Sahar S. , Mulvagh, Sharon L. , Pellikka, Patricia A , Hayes, Sharonne N

Mayo Clinic

Journal of Women's Health | February 11, 2013 | Volume: 22 | Issue: 2 | Pages: 173-183

10.1089/jwh.2012.3714 | PMID 23398128 Get It

Overall and Cancer-Specific Survival of Patients With Breast, Colon, Kidney, and Lung Cancers With and Without Chronic Lymphocytic Leukemia: A SEER Population-Based Study
Solomon, Benjamin , Rabe, Kari G. , Brewer, Jerry D., Cerhan, James R. , Slager, Susan L. , Shanafelt, Tait D. , Chaffee, Kari G. , Cerhan, James R

Mayo Clinic

Journal of Clinical Oncology | January 23, 2013 | Volume: 31 | Issue: 7 | Pages: 930-937

10.1200/jco.2012.43.4449 | PMID 23341508 Get It

Purpose Chronic lymphocytic leukemia (CLL) is associated with an increased risk of developing second cancers. However, it is unknown whether CLL alters the disease course of these cancers once they occur. Patients and Methods All patients with cancers of the breast (n = 579,164), colorectum (n = 412,366), prostate (n = 631,616), lung (n = 489,053), kidney (n = 95,795), pancreas (n = 82,116), and ovary (n = 61,937) reported to the SEER program from 1990 to 2007 were identified. Overall survival (OS; death resulting from any cause) and cancer-specific survival were examined, comparing patients with and without pre-existing CLL. Cancer-specific survival was evaluated for each tumor type in a site-specific manner (eg, death resulting from breast cancer in a patient with breast cancer). Results Patients with cancers of the breast (hazard ratio [HR], 1.70; P < .001), colorectum (HR, 1.65; P < .001), kidney (HR, 1.54; P < .001), prostate (HR, 1.92; P < .001), or lung (HR, 1.19; P < .001) had inferior OS if they had a pre-existing diagnosis of CLL after adjusting for age, sex, race, and disease stage. These results for OS remained significant for patients with cancers of the breast, colorectum, and prostate after excluding or censoring CLL-related deaths. Cancer-specific survival was also inferior for patients with cancers of the breast (HR, 1.41; P = .005) and colorectum (HR, 1.46; P < .001) who had pre-existing CLL after adjusting for age, sex, race, and disease stage. Conclusion Inferior OS and cancer-specific survival was observed for several common cancers in patients with pre-existing CLL. Additional studies are needed to determine the optimal management of these malignancies in patients with CLL and whether more aggressive screening or alternative approaches to adjuvant therapy are needed.
Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes
Achenbach, Sara J., Asmann, Yan W. , Camp, Nicola J. , Rabe, Kari G. , Goldin, Lynn R. , Call, Timothy G. , Cunningham, Julie M. , Wang, Alice H., Weinberg, J. Brice , Norman, Aaron D. , Link, Brian K. , Leis, José F., Vachon, Celine M. , Lanasa, Mark C., Caporaso, Neil E., Novak, Anne J. , Cerhan, James R. , Slager, Susan L. , Shanafelt, Tait D. , Kay, Neil E. , Vachon, Celine M. , Chaffee, Kari G. , Cerhan, James R , Link, Brian K , Norman, Aaron D

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 11, 2013 | Volume: 22 | Issue: 3 | Pages: 461-466

10.1158/1055-9965.epi-12-1217 | PMID 23307532 Get It

Abstract Background: Our genome-wide association study (GWAS) of chronic lymphocytic leukemia (CLL) identified 4 highly correlated intronic variants within the IRF8 gene that were associated with CLL. These results were further supported by a recent meta-analysis of our GWAS with two other GWAS of CLL, supporting the IRF8 gene as a strong candidate for CLL risk. Methods: To refine the genetic association of CLL risk, we conducted Sanger sequencing of IRF8 in 94 CLL cases and 96 controls. We then conducted fine mapping by genotyping 39 variants (of which 10 were identified from sequencing) in 745 CLL cases and 1,521 controls. We also assessed these associations with risk of other non-Hodgkin lymphoma (NHL) subtypes. Results: The strongest association with CLL risk was observed with a common single-nucleotide polymorphism (SNP) located within the 3′ untranslated region (UTR) of IRF8 (rs1044873, log additive OR = 0.7, P = 1.81 × 10−6). This SNP was not associated with the other NHL subtypes (all P &gt; 0.05). Conclusions: We provide evidence that rs1044873 in the IRF8 gene accounts for the initial GWAS signal for CLL risk. This association appears to be unique to CLL with little support for association with other common NHL subtypes. Future work is needed to assess functional role of IRF8 in CLL etiology. Impact: These data provide support that a functional variant within the 3′UTR of IRF8 may be driving the GWAS signal seen on 16q24.1 for CLL risk. Cancer Epidemiol Biomarkers Prev; 22(3); 461–6. ©2013 AACR.
Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
Tang, Jiang-bo, Stopfer, Jill E. , Lilli, Dana R., Hamel, Nancy , Monteiro, Álvaro N.A. , Messick, Troy E. , Powers, Jacquelyn M. , Yonker, Alexandria, Goldgar, David E., Davidson, H. Rosemarie, Nathanson, Katherine L. , Domchek, Susan M. , Tischkowitz, Marc D. , Couch, Fergus J. , Foulkes, William D. , Greenberg, Roger A. , Monteiro, Alvaro N , Nathanson, Katherine L

Mayo Clinic

Cancer Discovery | December 26, 2012 | Volume: 3 | Issue: 4 | Pages: 399-405

10.1158/2159-8290.cd-12-0421 | PMID 23269703 Get It

Abstract BRCA1 and BRCA2 are the most important breast and ovarian cancer susceptibility genes. Biallelic mutations in BRCA2 can lead to Fanconi anemia and predisposition to cancers, whereas biallelic BRCA1 mutations have not been confirmed, presumably because one wild-type BRCA1 allele is required during embryogenesis. This study describes an individual who was diagnosed with ovarian carcinoma at age 28 and found to have one allele with a deleterious mutation in BRCA1, c.2457delC (p.Asp821Ilefs*25), and a second allele with a variant of unknown significance in BRCA1, c.5207T&gt;C (p.Val1736Ala). Medical records revealed short stature, microcephaly, developmental delay, and significant toxicity from chemotherapy. BRCA1 p.Val1736Ala cosegregated with cancer in multiple families, associated tumors showed loss of wild-type BRCA1, and BRCA1 p.Val1736Ala showed reduced DNA damage localization. These findings represent the first validated example of biallelic deleterious human BRCA1 mutations and have implications for the interpretation of genetic test results. Significance: Accurate assessment of genetic testing data for BRCA1 mutations is essential for clinical monitoring and treatment strategies. Here, we report the first validated example of an individual with biallelic BRCA1 mutations, early-onset ovarian cancer, and clinically significant hypersensitivity to chemotherapy. Cancer Discov; 3(4); 399–405. ©2012 AACR. See related commentary by D'Andrea, p. 376 This article is highlighted in the In This Issue feature, p. 363
A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity
Guidugli, Lucia, Singh, Namit , Thompson, James E. , Erding, Catherine A., Engel, Christoph , Schmutzler, Rita K., Nathanson, Katherine L. , Radice, Paolo , Tonin, Patricia N. , Lindor, Noralane M. , Goldgar, David E., Pankratz, V. Shane , Domchek, Susan M. , Singer, Christian F. , Couch, Fergus J. , Thompson, James R. , Radice, Paolo , Nathanson, Katherine L , Engel, Christoph

Mayo Clinic

Cancer Research | October 30, 2012 | Volume: 73 | Issue: 1 | Pages: 265-275

10.1158/0008-5472.can-12-2081 | PMID 23108138 Get It

Abstract The relevance of many BRCA2 variants of uncertain significance (VUS) to breast cancer has not been determined due to limited genetic information from families carrying these alterations. Here, we classified six new variants as pathogenic or nonpathogenic by analysis of genetic information from families carrying 64 individual BRCA2 DNA binding domain (DBD) missense mutations using a multifactorial likelihood model of cancer causality. Next, we evaluated the use of a homology-directed DNA break repair (HDR) functional assay as a method for inferring the clinical relevance of VUS in the DBD of BRCA2 using 18 established nonpathogenic missense variants and all 13 established pathogenic missense mutations from the BRCA2 DBD. Compared with the known status of these variants based on the multifactorial likelihood model, the sensitivity of the HDR assay for pathogenic mutations was estimated at 100% [95% confidence interval (CI): 75.3%–100%] and specificity was estimated at 100% (95% CI: 81.5%–100%). A statistical classifier for predicting the probability of pathogenicity of BRCA2 DBD variants was developed using these functional results. When applied to 33 additional VUS, the classifier identified eight with 99% or more probability of nonpathogenicity and 18 with 99% or more probability of pathogenicity. Thus, in the absence of genetic evidence, a cell-based HDR assay can provide a probability of pathogenicity for all VUS in the BRCA2 DBD, suggesting that the assay can be used in combination with other information to determine the cancer relevance of BRCA2 VUS. Cancer Res; 73(1); 265–75. ©2012 AACR.
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia
Hickey, Christopher , Schwind, Sebastian , Radomska, Hanna S. , Dorrance, Adrienne M. , Santhanam, Ramasamy , Mishra, Anjali , Wu, Yue-Zhong, Alachkar, Houda , Maharry, Kati , Mrózek, Krzysztof , Eiring, Anna M. , Whitman, Susan P., Becker, Heiko , Perrotti, Danilo , Wu, Lai‐Chu , Zhao, Xi , Fehniger, Todd A. , Vij, Ravi , Byrd, John C. , Blum, William , Lee, L. James , Bloomfield, Clara D. , Garzon, Ramiro , Marcucci, Guido , Byrd, John C. , Nicolet, Deedra , Walker, Alison , Caligiuri, Michael A. , Fehniger, Todd A , Byrd, John C

Mayo Clinic

Blood | October 26, 2012 | Volume: 121 | Issue: 1 | Pages: 159-169

10.1182/blood-2012-05-428573 | PMID 23100311 Get It

AbstractRecently, we showed that increased miR-181a expression was associated with improved outcomes in cytogenetically normal acute myeloid leukemia (CN-AML). Interestingly, miR-181a expression was increased in CN-AML patients harboring CEBPA mutations, which are usually biallelic and associate with better prognosis. CEBPA encodes the C/EBPα transcription factor. We demonstrate here that the presence of N-terminal CEBPA mutations and miR-181a expression are linked. Indeed, the truncated C/EBPα-p30 isoform, which is produced from the N-terminal mutant CEBPA gene or from the differential translation of wild-type CEBPA mRNA and is commonly believed to have no transactivation activity, binds to the miR-181a-1 promoter and up-regulates the microRNA expression. Furthermore, we show that lenalidomide, a drug approved for myelodysplastic syndromes and multiple myeloma, enhances translation of the C/EBPα-p30 isoform, resulting in higher miR-181a levels. In xenograft mouse models, ectopic miR-181a expression inhibits tumor growth. Similarly, lenalidomide exhibits antitumorigenic activity paralleled by increased miR-181a expression. This regulatory pathway may explain an increased sensitivity to apoptosis-inducing chemotherapy in subsets of AML patients. Altogether, our data provide a potential explanation for the improved clinical outcomes observed in CEBPA-mutated CN-AML patients, and suggest that lenalidomide treatment enhancing the C/EBPα-p30 protein levels and in turn miR-181a may sensitize AML blasts to chemotherapy.
Improvement in Stroke Risk Prediction: Role of C-Reactive Protein and Lipoprotein-Associated Phospholipase A 2 in the Women's Health Initiative
McGinn, Aileen, Allison, Matthew , Ca, Tianxi, Curb, David, Hendrix, Susan L., Kaplan, Robert C. , Ko, Marcia, Martin, Lisa W. , Xue, Xiaonan , Kaplan, Robert C. , Wassertheil-Smoller, Sylvia W , Eaton, Charles B. , Allison, Matthew A , Warsinger-Martin, Lisa

Mayo Clinic

International Journal of Stroke | October 23, 2012 | Volume: 9 | Issue: 7 | Pages: 902-909

10.1111/j.1747-4949.2012.00860.x | PMID 23088183 Get It

Background Classification of risk of ischemic stroke is important for medical care and public health reasons. Whether addition of biomarkers adds to predictive power of the Framingham Stroke Risk or other traditional risk factors has not been studied in older women. Methods The Hormones and Biomarkers Predicting Stroke Study is a case-control study of blood biomarkers assayed in 972 ischemic stroke cases and 972 controls, nested in the Women's Health Initiative Observational Study of 93 676 postmenopausal women followed for an average of eight-years. We evaluated additive predictive value of two commercially available biomarkers: C-reactive protein and lipoprotein-associated phospholipase A 2 to determine if they added to risk prediction by the Framingham Stroke Risk Score or by traditional risk factors, which included lipids and other variables not included in the Framingham Stroke Risk Score. As measures of additive predictive value, we used the C-statistic, net reclassification improvement, category-less net reclassification improvement, and integrated discrimination improvement index. Results Addition of C-reactive protein to Framingham risk models or additional traditional risk factors overall modestly improved prediction of ischemic stroke and resulted in overall net reclassification improvement of 6·3%, (case net reclassification improvement = 3·9%, control net reclassification improvement = 2·4%). In particular, high-sensitivity C-reactive protein was useful in prediction of cardioembolic strokes (net reclassification improvement = 12·0%; 95% confidence interval 4·3–19·6%) and in strokes occurring in less than three-years (net reclassification improvement = 7·9%, 95% confidence interval 0·8–14·9%). Lipoprotein-associated phospholipase A 2 was useful in risk prediction of large artery strokes (net reclassification improvement = 19·8%, 95% confidence interval 7·4–32·1%) and in early strokes (net reclassification improvement = 5·8%, 95% confidence interval 0·4–11·2%). Conclusions C-reactive protein and lipoprotein-associated phospholipase A 2 can improve prediction of certain subtypes of ischemic stroke in older women, over the Framingham stroke risk model and traditional risk factors, and may help to guide surveillance and treatment of women at risk.